Literature DB >> 23262498

Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.

Lander Egaña-Gorroño1, Esteban Martínez, Bru Cormand, Tuixent Escribà, Jose Gatell, Mireia Arnedo.   

Abstract

OBJECTIVE: The impact of host genetic factors on the incidence of dyslipidemia in antiretroviral-naive HIV patients starting antiretroviral therapy (ART) is not clear. We assessed the role of single nucleotide polymorphisms (SNPs) identified from previous genome-wide association studies adjusting for the contribution of nongenetic factors.
METHODS: We assessed 192 SNPs in an HIV cohort who started ART (1997-2008) including a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (NNRTI). Patients had fasting plasma lipids, total cholesterol (T-Chol), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides measured prior to their ART initiation and after 1 year. A logistic regression model was constructed and multiple test was corrected using 10% false discovery rate (FDR). Haplotypes and gene interactions were analysed.
RESULTS: A total of 727 individuals were successfully genotyped (n = 381_PI-group; n = 346_NNRTI-group). Age and hepatitis C virus (HCV) coinfection were associated with increases and decreases in T-Chol and LDL-C (P < 0.01), respectively. Protease inhibitor containing ART showed an unfavourable association with T-Chol (P < 0.01) and triglycerides (P = 7.4E-4) and NNRTI-containing ART was favourably associated with HDL-C (P < 0.01). Moreover, SNPs in apolipoprotein B (APOB) were associated with an increase of LDL-C [rs10495712 (P = 3.18E-4); rs754524 (P = 1.26E-3)]. Six SNPs in three genes showed an association with a favourable effect on HDL-C levels when ART included NNRTI: ABCA1 (rs4149313, P = 2.97E-4), LIPC (rs1800588, P = 2.13E-3; rs473224, P = 3.06E-4; rs261336, P = 2.23E-3) and CETP (rs173539, P = 2.96E-3; rs3764261, P = 1.52E-3). After 10% FDR correction for multiple testing, one and six SNPs displayed significant associations with LDL-C and HDL-C, respectively.
CONCLUSION: In HIV-infected patients staring ART, one SNP in APOB was associated with an increase of LDL-C. SNPs in ABCA1/LIPC/CETP were favourably associated with HDL-C when ART included NNRTI. However, an unfavourable effect on T-Chol and triglyceride levels was observed when ART included protease inhibitor. The risk of hypercholesterolaemia increased with age and decreased with HCV coinfection. These findings might help to individualize the selection of ART.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23262498     DOI: 10.1097/QAD.0b013e32835d0da1

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Subset-Based Analysis Using Gene-Environment Interactions for Discovery of Genetic Associations across Multiple Studies or Phenotypes.

Authors:  Youfei Yu; Lu Xia; Seunggeun Lee; Xiang Zhou; Heather M Stringham; Michael Boehnke; Bhramar Mukherjee
Journal:  Hum Hered       Date:  2019-05-27       Impact factor: 0.444

2.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

3.  Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.

Authors:  L Egaña-Gorroño; E Martínez; P Domingo; M Loncà; T Escribà; J Fontdevila; F Vidal; E Negredo; J M Gatell; M Arnedo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 4.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

5.  Deciphering the molecular mechanisms involved in HIV-associated lipoatrophy by transcriptomics: a pilot study.

Authors:  Patricia Pérez-Matute; María Iñiguez; Emma Recio-Fernández; José-Antonio Oteo
Journal:  J Physiol Biochem       Date:  2017-01-10       Impact factor: 4.158

Review 6.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

7.  Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe.

Authors:  Danai Tavonga Zhou; Vitaris Kodogo; Kudzai Fortunate Vongai Chokuona; Exnevia Gomo; Olav Oektedalen; Babill Stray-Pedersen
Journal:  HIV AIDS (Auckl)       Date:  2015-05-13

Review 8.  The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.

Authors:  Elaine Regina Delicato de Almeida; Edna Maria Vissoci Reiche; Ana Paula Kallaur; Tamires Flauzino; Maria Angelica Ehara Watanabe
Journal:  Biomed Res Int       Date:  2013-11-12       Impact factor: 3.411

Review 9.  Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.

Authors:  Theodoros Kelesidis; Judith S Currier
Journal:  Endocrinol Metab Clin North Am       Date:  2014-09       Impact factor: 4.748

10.  Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.

Authors:  Rebecca B Marino; Lawrence A Kingsley; Shehnaz K Hussain; Jay H Bream; Sudhir Penogonda; Priya Duggal; Jeremy J Martinson
Journal:  BMC Res Notes       Date:  2015-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.